Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sprycel Dose Reduction To Be Considered By Oncology Cmte. During ASCO Road Show

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.

You may also be interested in...



Bristol Sprycel Receives Broad Committee Support For Leukemia Indications

FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.

Bristol Sprycel Receives Broad Committee Support For Leukemia Indications

FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting

FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel